Inhaled Antibiotic ARIKAYCE Gets FDA Priority Review for Earlier Use in MAC Lung Disease, with Decision Due January

FDA granted priority review to ARIKAYCE’s full approval bid for MAC lung disease, with a decision due Jan. 28, 2027. What patients should know.

Have A Referral?